These findings confirmed that PAICS is an essential gene and provided a novel and feasible therapeutic solution for NSCLC patients carrying wild‐type EGFR, which are not suitable for current targeted therapies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.